Ipsen (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ipsen" in English language version.

refsWebsite

Global rank English rank

low place

low place

4web.archive.org

1^st place

1^st place

605^th place

3,401^st place

3usinenouvelle.com

4,154^th place

low place

49^th place

47^th place

234^th place

397^th place

low place

low place

1lechorepublicain.fr

low place

low place

1fondation-ipsen.org

low place

low place

low place

low place

1businesswire.com

615^th place

407^th place

1zonebourse.com

4,958^th place

low place

1fiercepharma.com

low place

8,921^st place

634^th place

432^nd place

1pharmaceuticalcommerce.com

low place

low place

1clinicaltrials.gov

5,225^th place

4,062^nd place

1wallstreet-online.de

low place

low place

1leave-russia.org

low place

low place

businesswire.com

"Aux États-Unis, Ipsen transfère ses activités de R&D à Cambridge, Massachusetts, en 2014". businesswire.com. 26 September 2013. Retrieved 13 December 2022.

clinicaltrials.gov

Ipsen (9 May 2024). A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid (Report). clinicaltrials.gov. Archived from the original on 2 May 2024. Retrieved 11 June 2024.

euronext.com

live.euronext.com

"IPSEN €100.40 | Euronext exchange Live quotes". live.euronext.com. Retrieved 13 December 2022.

evaluate.com

"Ipsen | Evaluate".

fiercepharma.com

Dunleavy, Kevin (9 January 2023). "JPM23: Ipsen scoops up liver disease specialist Albireo for $952M". Fierce Pharma. Retrieved 31 January 2023.

fondation-ipsen.org

"Rare Disease Foundation – Homepage". Fondation Ipsen. Retrieved 13 December 2022.

ipsen.com

"FY 2023 results" (PDF). Ipsen.
"Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases". Ipsen. Retrieved 31 January 2023.
"Strong Full-Year 2022 Results and Guidance for 2023 | Ipsen Global". Global. Retrieved 11 June 2024.
"Building on solid FY 2023 results, Ipsen anticipates four launches in 2024". Global. Retrieved 11 June 2024.
"Shareholders Information at Ipsen | Valuable Insights for Shareholders". Global. Retrieved 11 June 2024.
"Our Products". Ipsen. Retrieved 13 December 2022.
"Research and Development". Ipsen. Retrieved 13 December 2022.

leave-russia.org

"Ipsen". Leave Russia. Retrieved 10 December 2024.

lechorepublicain.fr

France, Centre (17 February 2015). "Ipsen a engagé plus de 40 millions d'euros d'investissement entre 2012 et 2016". lechorepublicain.fr. Retrieved 13 December 2022.

lesechos.fr

lesechos.fr

"Ipsen réussit son virage vers la cancérologie". Les Echos (in French). 11 September 2017. Retrieved 13 December 2022.
"Ipsen, le défi américain". Les Echos (in French). 1 October 2015. Retrieved 13 December 2022.
"Ipsen réussit son virage vers la cancérologie". Les Echos (in French). 11 September 2017. Retrieved 9 November 2023.

investir.lesechos.fr

"Ipsen relève ses objectifs pour 2024 et négocie la vente de son pôle santé familiale". Investir (in French). 11 February 2022. Retrieved 13 December 2022.

nature.com

"Ipsen: A dynamic, fast-growing specialty care powerhouse".

pharmaceuticalcommerce.com

"Ipsen Nabs FDA Approval for NALIRIFOX in First-Line Metastatic Pancreatic Adenocarcinoma". Pharmaceutical Commerce. Archived from the original on 13 March 2024. Retrieved 11 March 2024.

reuters.com

"France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 billion deal". Reuters. 8 January 2017. Retrieved 9 November 2023.
"Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion". Reuters. 25 February 2019. Retrieved 13 December 2022.

usinenouvelle.com

Nouvelle, L'Usine (10 November 1994). "PharmacieBeaufour-Ipsen s'installe outre-Manche avec PortonConnu pour sa recherche, Porton International va ouvrir au septième groupe pharmaceutique français les marchés britannique et américain. Le ticket d'entrée: 550millions de francs" (in French). {{cite journal}}: Cite journal requires |journal= (help)
Nouvelle, L'Usine (29 May 2003). "Ipsen succède à Beaufour Ipsen" (in French). {{cite journal}}: Cite journal requires |journal= (help)
Nouvelle, L'Usine (18 April 2019). "Avec l'acquisition de Clementia, Ipsen se renforce dans les maladies rares" (in French). {{cite journal}}: Cite journal requires |journal= (help)

usnews.com

"US FDA Approves French Drugmaker Ipsen's Rare Bone Disorder Drug". US News. Archived from the original on 17 August 2023. Retrieved 13 March 2024.

wallstreet-online.de

"Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis". wallstreet-online.de (in German). 10 June 2024. Archived from the original on 11 June 2024. Retrieved 11 June 2024.

web.archive.org

"US FDA Approves French Drugmaker Ipsen's Rare Bone Disorder Drug". US News. Archived from the original on 17 August 2023. Retrieved 13 March 2024.
"Ipsen Nabs FDA Approval for NALIRIFOX in First-Line Metastatic Pancreatic Adenocarcinoma". Pharmaceutical Commerce. Archived from the original on 13 March 2024. Retrieved 11 March 2024.
Ipsen (9 May 2024). A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid (Report). clinicaltrials.gov. Archived from the original on 2 May 2024. Retrieved 11 June 2024.
"Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis". wallstreet-online.de (in German). 10 June 2024. Archived from the original on 11 June 2024. Retrieved 11 June 2024.

zonebourse.com

Bourse, Zone (18 April 2019). "Ipsen boucle son acquisition record du canadien Clementia | Zonebourse". zonebourse.com (in French). Retrieved 13 December 2022.